Temporality of body mass index, blood tests, comorbidities and medication use as early markers for pancreatic ductal adenocarcinoma (PDAC): a nested case–control study

Temporality of body mass index, blood tests, comorbidities and medication use as early markers for pancreatic ductal adenocarcinoma (PDAC): a nested case–control study

<p><strong>Objective</strong> Prior studies identified clinical factors associated with increased risk of pancreatic ductal adenocarcinoma (PDAC). However, little is known regarding their time-varying nature, which could inform earlier diagnosis. This study assessed temporality of...

Full description

Bibliographic Details
Main Authors:	Tan, PS, Garriga, C, Clift, A, Liao, W, Patone, M, Coupland, C, Bashford-Rogers, R, Sivakumar, S, Hippisley-Cox, J
Format:	Journal article
Language:	English
Published:	BMJ Publishing 2022

Similar Items

Predicting the risk of pancreatic cancer in adults with new-onset diabetes: development and internal-external validation of a clinical risk prediction model
by: Clift, AK, et al.
Published: (2024)

Targeting Pancreatic Ductal Adenocarcinoma (PDAC)
by: Sofia Parrasia, et al.
Published: (2021-01-01)

Imaging p53 in Pancreatic Ductal Adenocarcinoma (PDAC)
by: Koustoulidou, S, et al.
Published: (2016)

Clinically impactful metabolic subtypes of pancreatic ductal adenocarcinoma (PDAC)
by: Jannat Pervin, et al.
Published: (2023-10-01)

Identifying symptoms associated with diagnosis of pancreatic exocrine and neuroendocrine neoplasms: a nested case-control study of the UK primary care population
by: Liao, W, et al.
Published: (2021)

The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC.
by: Matthew Brown, et al.
Published: (2020-01-01)

Regulatory role of RNA modifications in the treatment of pancreatic ductal adenocarcinoma (PDAC)
by: Hao Chen, et al.
Published: (2023-11-01)

MicroRNAs as Indicators of Malignancy in Pancreatic Ductal Adenocarcinoma (PDAC) and Cystic Pancreatic Lesions
by: Christian Prinz, et al.
Published: (2022-08-01)

Developing a model of acid-driven evolution for Pancreatic Ductal Adenocarcinoma (PDAC)
by: Blaszczak, WZ
Published: (2022)

The Use of Personalized Medicine in Pancreatic Ductal Adenocarcinoma (PDAC): New Therapeutic Opportunities
by: Inês Mendes, et al.
Published: (2024-12-01)

Adult Pancreatoblastoma: Clinical Insights and Outcomes Compared to Pancreatic Ductal Adenocarcinoma (PDAC)
by: Han Yin, et al.
Published: (2024-08-01)

Expression of sorting nexin 1 in pancreatic ductal adenocarcinoma and its mechanism in promoting PDAC progress
by: PAN Hong, et al.
Published: (2023-03-01)

A pilot study of estrogen receptor (ER) expression in pancreatic ductal adenocarcinoma (PDAC)
by: Chan, Kai Siang, et al.
Published: (2022)

Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms
by: Sivakumar, S, et al.
Published: (2025)

Distinct immune cell infiltration patterns in pancreatic ductal adenocarcinoma (PDAC) exhibit divergent immune cell selection and immunosuppressive mechanisms
by: Shivan Sivakumar, et al.
Published: (2025-02-01)

Neurotensin is a Versatile Modulator of In Vitro Human Pancreatic Ductal Adenocarcinoma Cell (PDAC) Migration
by: Tatjana Mijatovic, et al.
Published: (2007-01-01)

Circulating Tumor Cell Subpopulations Predict Treatment Outcome in Pancreatic Ductal Adenocarcinoma (PDAC) Patients
by: Ian M. Freed, et al.
Published: (2023-09-01)

WDR79 promotes aerobic glycolysis of pancreatic ductal adenocarcinoma (PDAC) by the suppression of SIRT4
by: Yin Wenke, et al.
Published: (2023-01-01)

MSP-RON Signaling Is Activated in the Transition From Pancreatic Intraepithelial Neoplasia (PanIN) to Pancreatic Ductal Adenocarcinoma (PDAC)
by: Ce Li, et al.
Published: (2019-02-01)

Role of carbonic anhydrase catalysis and gap junctional coupling in regulating ph in pancreatic ductal adenocarcinoma (PDAC)
by: Dovmark, T
Published: (2017)

Minimally invasive determination of pancreatic ductal adenocarcinoma (PDAC) subtype by means of circulating cell‐free RNA
by: Martin Metzenmacher, et al.
Published: (2025-02-01)

Advantage of oncological outcome of robotic-assisted pancreatoduodenectomy (RPD) in stage I pancreatic ductal adenocarcinomas (PDAC)
by: Jingfeng Li, et al.
Published: (2022-09-01)

Role of epithelial mesenchymal transition (EMT) in pancreatic ductal adenocarcinoma (PDAC): is tumor budding the missing link?
by: Eva eKaramitopoulou
Published: (2013-09-01)

Impact of N‑Terminal PEGylation on Synthesis and Purification of Peptide-Based Cancer Epitopes for Pancreatic Ductal Adenocarcinoma (PDAC)
by: Omar F. Luna, et al.
Published: (2024-08-01)

Establishment and characterization of a novel multidrug-resistant pancreatic ductal adenocarcinoma cell line, PDAC-X1
by: Cheng Yu, et al.
Published: (2024-07-01)

Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to KRAS mutational status
by: E.B. Faber, et al.
Published: (2024-06-01)

Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL).
by: Hayley J Hawkins, et al.
Published: (2024-01-01)

Niraparib perturbs autophagosome-lysosome fusion in pancreatic ductal adenocarcinoma and exhibits anticancer potential against gemcitabine-resistant PDAC
by: Zehui Yao, et al.
Published: (2025-01-01)

Segmentation of pancreatic ductal adenocarcinoma (PDAC) and surrounding vessels in CT images using deep convolutional neural networks and texture descriptors
by: Tahereh Mahmoudi, et al.
Published: (2022-02-01)

Novel Histone Deacetylase (HDAC) Inhibitor Induces Apoptosis and Suppresses Invasion via E-Cadherin Upregulation in Pancreatic Ductal Adenocarcinoma (PDAC)
by: Katja Schiedlauske, et al.
Published: (2024-06-01)

Evaluation of MMR Status and PD-L1 Expression Using Specimens Obtained by EUS-FNB in Patients with Pancreatic Ductal Adenocarcinoma (PDAC)
by: Alina Constantin, et al.
Published: (2022-01-01)

Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation.
by: Juan Pablo Arnoletti, et al.
Published: (2022-01-01)

Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation
by: Juan Pablo Arnoletti, et al.
Published: (2022-01-01)

The T cell architecture of pancreatic ductal adenocarcinoma
by: Sivakumar, S, et al.
Published: (2019)

The T-cell architecture of pancreatic ductal adenocarcinoma
by: Sivakumar, S, et al.
Published: (2019)

Pseudotime dynamics in pancreatic ductal adenocarcinoma reveal different mechanisms of hindrance in immunity through bifurcation of regulatory and cytotoxic T-cell differentiation
by: Jainarayanan, AK, et al.
Published: (2021)

Open-source curation of a pancreatic ductal adenocarcinoma gene expression analysis platform (pdacR) supports a two-subtype model
by: Luke A. Torre-Healy, et al.
Published: (2023-02-01)

Overexpression and Tyr421-phosphorylation of cortactin is induced by three-dimensional spheroid culturing and contributes to migration and invasion of pancreatic ductal adenocarcinoma (PDAC) cells
by: Katharina Stock, et al.
Published: (2019-03-01)

Lysine demethylase 2 (KDM2B) regulates hippo pathway via MOB1 to promote pancreatic ductal adenocarcinoma (PDAC) progression
by: Ming Quan, et al.
Published: (2020-01-01)

Immuno-phenotypes of Pancreatic Ductal Adenocarcinoma: Metaanalysis of transcriptional subtypes
by: De Santiago, I, et al.
Published: (2018)